XT
RPRX icon

XTX Topco’s Royalty Pharma RPRX Stock Holding History

XTX Topco’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-145,144
Closed -$5.12M – 3722
2025
Q3 		$5.12M Buy
+145,144
New +$5.25M 0.27% 27
2025
Q2 		– Sell
-53,119
Closed -$1.65M – 3045
2025
Q1 		$1.65M Buy
+53,119
New +$1.68M 0.08% 320
2023
Q3 		– Sell
-20,911
Closed -$643K – 1947
2023
Q2 		$643K Buy
20,911
+11,636
+125% +$394K 0.12% 238
2023
Q1 		$334K Sell
9,275
-2,971
-24% -$110K 0.07% 568
2022
Q4 		$484K Buy
12,246
+6,049
+98% +$252K 0.1% 313
2022
Q3 		$249K Buy
+6,197
New +$265K 0.06% 624
2022
Q1 		– Sell
-10,280
Closed -$410K – 913
2021
Q4 		$410K Buy
+10,280
New +$399K 0.23% 109

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XTX Topco's RPRX Position: Q4 2025 in Review

XTX Topco sold out of Royalty Pharma (RPRX) in Q4 2025, closing a stake of 145,144 shares — an estimated $5.12M sold.

XTX Topco first reported a position in RPRX in Q4 2021 and held it in 7 quarters. The position peaked at $5.12M in Q3 2025. 538 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

  • XTX Topco reported no remaining Royalty Pharma position as of Q4 2025 after selling out during the quarter.
  • XTX Topco sold 145,144 Royalty Pharma shares in Q4 2025, an estimated $5.12M.
  • XTX Topco first reported a position in Royalty Pharma in Q4 2021 and held it in 7 quarters.
  • XTX Topco's Royalty Pharma position peaked at $5.12M in Q3 2025.
  • 538 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on XTX Topco's 13F filing for Q4 2025, filed 17 Feb 2026.